Biosimilar Avastin Is Launched In India
Cadila Pharmaceuticals Announces Entry
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
You may also be interested in...
After launching bevacizumab, rituximab and teriparatide biosimilars in the last two months, Cadila Pharma has added to the portfolio with the launch of Cadalimab (adalimumab) in India.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.